Management of Spleen Involvement in Systemic Lupus Erythematosus (SLE)

Introduction to SLE Management

The European League Against Rheumatism recommends spleen involvement in SLE should be managed according to the specific manifestation, with splenectomy reserved only as a last resort option for cases of severe, refractory thrombocytopenia that fail to respond to medical therapy 1, 2

Thrombocytopenia and autoimmune hemolytic anemia (AIHA) are the most common hematological manifestations in SLE that may involve the spleen 1, 2

The American College of Rheumatology recommends moderate to high doses of glucocorticoids (GC) in combination with immunosuppressive (IS) agents for the treatment of thrombocytopenia in SLE 1, 2
Initial therapy with pulses of intravenous methylprednisolone (1-3 days) is recommended 1
Immunosuppressive options to combine with GC include azathioprine (AZA) 1, 2, mycophenolate mofetil (MMF) 1, 2, and cyclosporine 1, 2
Intravenous immunoglobulin (IVIG) may be considered in cases with inadequate response to high-dose GC 1, 2
Rituximab (RTX) should be considered for patients with failure to reach platelet count >50,000/mm³ despite GC therapy 1, 2
Cyclophosphamide (CYC) may also be considered in refractory cases 1, 2

AIHA is less common than thrombocytopenia in SLE but follows the same treatment principles 1, 2

Regular assessment of disease activity using validated indices is recommended 3
All SLE patients should receive hydroxychloroquine (HCQ) as the backbone of treatment unless contraindicated 3, 4
Dose of HCQ should not exceed 5 mg/kg real body weight to minimize risk of retinal toxicity 4
Monitor for infections, as SLE patients have increased risk due to both disease and immunosuppressive therapy 3

Treatment of thrombocytopenia in SLE is typically lengthy and often characterized by relapses during GC tapering 1, 2
Autoimmune leukopenia is common in SLE but rarely needs treatment; careful workup is recommended to exclude other causes (especially drug-induced) 1, 2
The goal of treatment should be remission or low disease activity to prevent organ damage accrual 4, 5
Consider antiphospholipid antibody status when managing SLE patients with hematological manifestations, as this may influence treatment approach 5

Avoid prolonged use of high-dose glucocorticoids due to risk of irreversible organ damage 4
Risks of glucocorticoid therapy increase substantially with doses >7.5 mg/day prednisone equivalent 4
Carefully assess adherence to drug treatment, especially hydroxychloroquine, as non-adherence is associated with higher flare rates 5
Splenectomy should not be considered early in the treatment algorithm due to increased risk of infections and potential for post-splenectomy thrombosis 1, 2